natgillin/translations-raw huggingface dataset:
Andel af serumfosforrespondere ved uge 12 (%)
Proportion of serum phosphorus responders at Week 12 (%)
Andel der absorberes transmukosalt
Fraction absorbed transmucosally
Andel med 12-ugers bekræftet handikapprogression
Proportion with 12-week confirmed disability progression
Andel med 24-ugers bekræftet invaliditetsprogression
Proportion with 24 week confirmed disability progression
Andel med attakker
0.71 (0.55, 0.93)
Andel med ferritin
Proportion with ferritin
Andel med invaliditetsprogression bekræftet efter 3 måneder †
Proportion with 3-month Confirmed Disability Progression
Andel med invaliditetsprogression bekræftet efter 3 måneder†
Proportion with 3-month Confirmed Disability Progression
Andel med progression 1(24- ugers bekræftelse)
Proportion progressed1(24-week confirmation)
Andel med progression1(12- ugers bekræftelse; primært resultat)
Proportion progressed1(12-week confirmation; primary outcome)
Andel patienter
Propotion of Patients
Andel patienter med serumurinsyreniveauer <357 µmol/l (6,0 mg/dl) Sidste tre månedlige besøg
Proportion of Patients with Serum Uric Acid Levels <6.0 mg/dL (357 µmol/L) Last Three Monthly Visits
Andel patienter med øget ALAT-aktivitet i kliniske studier
Proportion of patients with increased ALT activity in clinical studies
Andel patienter, der vandt:
Proportion of patients who gained:
Andel personer, der havde opnået normalt Hb ved uge 12 (%)
Proportion of subjects that achieved normalised Hb at Week 12 (%)
Andel personer, havde opnået en Hb-ændring på
Proportion of subjects that achieved
Andel, der opnåede HbA1c < 7 %
Proportion Achieving HbA1c <7
Andel, der overlevede
Proportion Surviving
Andele af patienter (%) der opnåede målet HbA1c <7%
Proportions of patients achieving HbA1c <7% targets (%)
Andelen af enzalutamidbehandlede patienter med registrerbar sygdom ved baseline, der havde en objektiv bløddelsrespons, var 58,8 % (95 % KI: 53,8; 63,7) sammenlignet med 5,0 % (95 % KI: 3,0; 7,7) af patienterne, der fik placebo.
The proportion of enzalutamide-treated patients with measurable disease at baseline who had an objective soft tissue response was 58.8% (95% CI: 53.8, 63.7) compared with 5.0% (95% CI: 3.0, 7.7) of patients receiving placebo.
Andelen af forsøgspersoner med bekræftet PSA-respons var højere i ZYTIGA-gruppen end i placebogruppen (62 % vs.
The proportion of subjects with a confirmed PSA response was greater in the ZYTIGA group than in the placebo group (62% vs.
Andelen af forsøgspersoner med hiv 1-RNA < 50 kopier/ml i uge 48 (TLOVR) var 72,2 % (26/36).
The proportion of subjects with HIV-1 RNA < 50 copies/mL at week 48 (TLOVR) was 72.2% (26/36).
Andelen af forsøgspersoner med hSBA ≥ 1:8 var ikke-inferiør til ACWY-PS med hensyn til alle fire serogrupper og statistisk overlegen med hensyn til serogrupperne A og Y (tabel 10).
The proportion of subjects with hSBA ≥ 1:8 was non-inferior to ACWY-PS for all four serogroups and statistically superior for serogroups A and Y (Table 10).
Andelen af forsøgspersoner, der fik transfusion til håndtering af anæmi var 3 % af forsøgspersonerne i de Victrelis-indeholdende arme sammenlignet med < 1 % af forsøgspersonerne, der kun fik peginterferon alfa-2b og ribavirin.
The proportion of subjects who received a transfusion for the management of anaemia was 3% of subjects in the Victrelis-containing arms compared to < 1% of subjects receiving peginterferon alfa-2b and ribavirin alone.
Andelen af forsøgspersoner, der krævede behandling for et udbrud af arthritis urica (APEX-studiet og FACT-studiet), var numerisk lavere i de grupper, der opnåede et gennemsnitligt serumuratniveau efter baseline på <357 µmol/l (6,0 mg/dl), <298 µmol/l (5,0 mg/dl) eller <238 µmol/l (4,0 mg/dl) sammenlignet med den gruppe, der opnåede et gennemsnitligt serumuratniveau efter baseline på ≥
The proportion of subjects requiring treatment for a gout flare (APEX and FACT Study) was numerically lower in the groups that achieved an average post-baseline serum urate level <6.0 mg/dL,
Andelen af IKERVIS-behandlede patienter med en 3- graders forbedring i CFS-score ved måned 6 (fra 4 til 1) var 28,8 %, sammenlignet med 9,6 % af kontrolbehandlede forsøgspersoner, men da dette var en efterfølgende analyse, begrænser det resultatets robusthed.
The proportion of IKERVIS-treated patients with a 3-grade improvement in CFS score at Month 6 (from 4 to 1) was 28.8%, compared to 9.6% of vehicle-treated subjects, but this was a post-hoc analysis, which limits the robustness of this outcome.
Andelen af ikke-CABG-relaterede større eller mindre blødning (TIMI):
Non-CABG-related TIMI major or minor bleeding rates:
Andelen af ikke-CABG-relaterede større eller mindre blødning(TIMI) :
Non-CABG-related TIMI major or minor bleeding rates:
Andelen af ikke-CABG-relaterede større eller mindre blødninger (TIMI) :
Non-CABG-related TIMI major or minor bleeding rates:
Andelen af ikke-CABG-relaterede større eller mindre blødninger (TIMI):
Non-CABG-related TIMI major or minor bleeding rates:
Andelen af ILS- bivirkninger med fatalt udfald var 38,6 %.
The proportion of ILD-type events with a fatal outcome was 38.6%.
Andelen af natlige hypoglykæmiske hændelser var signifikant lavere ved behandling med Xultophy sammenlignet med insulin glargin (estimeret behandlingsratio 0,17; p < 0,001).
The rate of nocturnal hypoglycaemic events was significantly lower with Xultophy compared to insulin glargine (estimated treatment ratio 0.17, p<0.001).
Andelen af patienter behandlet med MabThera, som viste minimal klinisk relevant ændring (MCID) i HAQ-DI (defineret som et fald i individuel total score på > 0,22) var også højere end hos patienter, som fik methotrexat alene (tabel 12).
The proportions of MabThera treated patients showing a minimal clinically important difference (MCID) in HAQ-DI (defined as an individual total score decrease of >0.22) was also higher than among patients receiving methotrexate alone (Table 12).
Andelen af patienter i CAL30001 med GSS-score på < 2 eller  2 og suppression til < 50 kopier/ml ved uge 48 var sammenlignelige i de 2 behandlingsarme, abacavir én gang daglig og abacavir 2 gange daglig.
Similar proportions of patients in the once-daily and twice-daily abacavir arms of CAL30001 had GSS scores of <2 or 2 and successfully suppressed to <50 copies/mL by Week 48.
Andelen af patienter i patientpopulationen med tumorer af KRAS- vildtypen, som kunne vurderes med hensyn til KRAS-status, var 58%.
The proportion of patients with KRAS wild-type tumours from the patient population evaluable for KRAS status comprised 58%.
Andelen af patienter i symptomatisk remission fra mani var sammenlignelig mellem Aripiprazole og lithium eller haloperidol ved uge 12.
Aripiprazole also demonstrated a comparable proportion of patients in symptomatic remission from mania as lithium or haloperidol at week 12.
Andelen af patienter med ACR 20/50/70 (respons i studie PALACE 1, PALACE 2 og PALACE 3, og de samlede data fra studie PALACE 1, PALACE 2 og PALACE 3) for apremilast 30 mg to gange dagligt efter uge 16 vises i tabel 3.
The proportion of patients with ACR 20/50/70 (responses in Studies PALACE 1, PALACE 2 and PALACE 3, and the pooled data for studies PALACE 1, PALACE 2 and PALACE 3) for apremilast 30 mg twice daily at Week 16 are shown in Table 3.
Andelen af patienter med ACR 20/50/70 (respons i studie PALACE 1, PALACE 2 og PALACE 3, og de samlede data fra studie PALACE 1, PALACE 2 og PALACE 3), for apremilast 30 mg to gange dagligt efter uge 16 vises i tabel 3.
The proportion of patients with ACR 20/50/70 (responses in Studies PALACE 1, PALACE 2 and PALACE 3, and the pooled data for studies PALACE 1, PALACE 2 and PALACE 3) for apremilast 30 mg twice daily at Week 16 are shown in Table 3.
Andelen af patienter med ACR-respons i studie PALACE 1, PALACE 2 og PALACE 3 og samlede studier efter uge 16
Proportion of patients with ACR responses in studies PALACE 1, PALACE 2 and PALACE 3 and pooled studies at Week 16
Andelen af patienter med ALAT- normalisering ved uge 192 i TDF-TDF-gruppen var 75,8% (25/33) blandt de patienter, som var HBeAg-positive ved baseline, og 100,0% (2 af 2 patienter) blandt dem, der var HBeAg-negative ved baseline.
The proportion of subjects with ALT normalization at week 192 in the TDF-TDF group was 75.8% (25/33) among those who were HBeAg positive at baseline and 100.0% (2 of 2 subjects) among those who were HBeAg negative at baseline.
Andelen af patienter med alvorlig hypoglykæmi pr. patienteksponeringsår (procentdel af patienter) var 0,01 (1 patient ud af 291) for Xultophy og 0,00 (0 patienter ud af 199) for GLP-1 receptoragonister.
The rate per patient year of exposure (percentage of patients) of severe hypoglycaemia was 0.01 (1 patient out of 291) for Xultophy and 0.00 (0 patients out of 199) for GLP-1 receptor agonists.
Andelen af patienter med alvorlige bivirkninger balancerede mellem de 2 behandlingsgrupper (tocilizumab 11,7% mod adalimumab 9,9%).
The proportion of patients with serious adverse events was balanced between the treatment groups (tocilizumab 11.7% vs. adalimumab 9.9%).
Andelen af patienter med CMV viræmi/syndrome var 13,5 %.
The proportion of patients with CMV viraemia/syndrome was 13.5%.
Andelen af patienter med en forbedring i forsøgsøjet på mindst 15 bogstaver i forhold til BCVA (Best Corrected Visual Acuity) ved baseline var efter 8 uger mere end 6 gange højere med OZURDEX (42,9 %) end med sham (6,6 %) (p < 0,001).
The proportion of patients with at least 15 letters improvement from baseline BCVA in the study eye at week 8 was more than 6-fold higher with OZURDEX (42.9%) compared to
Andelen af patienter med en rapporteret forlængelse af PR- intervallet > 200 ms i dette studie spændte fra 3/22 (14 %) (dag 3) til 8/21 (38 %) (dag 14).
The proportion of patients with a reported PR interval prolongation > 200 ms in this study ranged from 3/22 (14%) (day 3) to 8/21 (38%) (day14).
Andelen af patienter med gennemsnitligt ≥3 spontane, fuldstændige afføringer (SCBM) om ugen (dvs. respondenter) i den 24-ugers dobbeltblindede behandlingsfase var ikke statistisk forskellig (p=0,367) mellem Resolor-gruppen (25,1 %) og placebogruppen (20,7 %).
The proportion of patients with an average weekly frequency of ≥3 Spontaneous Complete Bowel Movements (SCBMs) per week (ie, responders) over the 24-week double-blind treatment phase was not statistically different (p=0.367) between the prucalopride (25.1%) and placebo (20.7%) treatment groups.
Andelen af patienter med gennemsnitligt ≥3 spontane, fuldstændige afføringer (SCBM) om ugen (dvs. respondenter) i den 24-ugers dobbeltblindede behandlingsfase var ikke statistisk forskellig (p=0,367) mellem Resolor-gruppen (25,1 %) og placebogruppen (20,7 %).
The proportion of patients with an average weekly frequency of ≥3 Spontaneous Complete Bowel Movements (SCBMs) per week (ie, responders) over the 24-week double-blind treatment phase was not statistically different (p=0.367) between the Resolor (25.1%) and placebo (20.7%) treatment groups.
Andelen af patienter med infektioner i C0168T72 svarede til andelen i studiet med børn med Crohns sygdom (REACH), men var højere end andelen i studierne med voksne med colitis ulcerosa (ACT 1 og ACT 2).
The proportion of patients with infections in C0168T72 was similar to that in the paediatric Crohn’s disease study (REACH) but higher than the proportion in the adults ulcerative colitis studies (ACT 1 and ACT 2).
Andelen af patienter med IOP-målinger på under 18 mmgHg var større i SIMBRINZA-gruppe end i Brinzolamid- gruppen på 9 ud af 12 evalueringer i måned 6, og var større i SIMBRINZA-gruppen end i Brimonidin- gruppen ved alle 12 evalueringer i løbet af måned 6.
The percentages of patients with an IOP measurement less than 18 mmHg were greater in the SIMBRINZA group than in the Brinzolamide group at 9 of 12 assessments through Month 6 and were greater in the SIMBRINZA group than in the Brimonidine group at all 12 assessments through Month 6.
Andelen af patienter med mindst én grad 3 eller 4 leverrelateret laboratorietoksicitet var 8,3 % for ”nevirapin 2 gange daglig” og 4,5 % for efivarenz.
The proportion of patients with at least one grade 3 or 4 liver-associated laboratory toxicity was 8.3 % for nevirapine twice daily and 4.5 % for efavirenz.
Andelen af patienter med mindst én SRE (eksklusiv hyperkalcæmi) var 29,8 % i den zoledronsyrebehandlede gruppe sammenlignet med 49,6 % i placebogruppen (p=0,003).
The proportion of patients with at least one SRE (excluding hypercalcaemia) was 29.8 % in the zoledronic acid-treated group versus 49.6 % in the placebo group (p=0.003).
Andelen af patienter med påviseligt talimogen laherparepvec-DNA i blod og urin var højst under den anden cyklus.
The proportion of patients with detectable talimogene laherparepvec DNA in blood and urine was highest during the second cycle.
Andelen af patienter med slimhindeheling i uge 26 var signifikant større i grupperne, der fik infliximab plus AZA (43,9 %; p < 0,001) eller infliximab-monoterapi (30,1 %; p = 0,023) sammenlignet med AZA- monoterapigruppen (16,5 %).
The proportions of patients with mucosal healing at week 26 were significantly greater in the infliximab plus AZA combination (43.9%, p < 0.001) and infliximab monotherapy groups (30.1%, p=0.023) compared to the AZA monotherapy group (16.5%).
Andelen af patienter med smertelindring var statistisk signifikant højere i ZYTIGA-gruppen end i placebo-gruppen (44 % vs.
The proportion of patients with pain palliation was statistically significantly higher in the ZYTIGA group than in the placebo group (44% vs.
Andelen af patienter med sygdomsopblussen i del II
Proportion of patients with disease flare in Part II
Andelen af patienter som havde post-behandling ALAT-stigninger, i forbindelse med en stigning i bilirubin- niveauer, var lav og ensartet hos patienter, der modtog enten lamivudin eller placebo.
The proportion of patients who had post-treatment ALT elevations in association with an increase in bilirubin levels was low and similar in patients receiving either lamivudine or placebo.
Andelen af patienter som havde post-behandling ALAT-stigninger, i forbindelse med en stigning i billirubinniveauer, var lav og ensartet hos patienter der modtog enten lamivudin eller placebo.
The proportion of patients who had post-treatment ALT elevations in association with an increase in bilirubin levels was low and similar in patients receiving either lamivudine or placebo.
Andelen af patienter som opretholdt CCyR i et år var 97% (95% KI: [94%-99%]) og 90% (95% KI: [86%-95%]) i to år.
The proportion of patients who maintained CCyR for 1 year was 97% (95% CI: [94%-99%]) and for 2 years was 90% (95% CI: [86%-95%]).
Andelen af patienter som seponerede behandling på grund af bivirkninger, var 3,3% for abataceptbehandlede patienter og 2,0% for placebobehandlede.
The proportion of patients who discontinued treatment due to ARs was 3.3% for abatacept- treated patients and 2.0% for placebo-treated patients.
Andelen af patienter uden emesis 0-72 timer efter operation var den samme efter palonosetron 1 mcg/kg og 3 mcg/kg (88 % versus 84 %).
The proportion of patients without emesis during 0-72 hours post-operatively was similar after palonosetron 1 mcg/kg or 3 mcg/kg (88% vs 84%).
Andelen af patienter, der fik cisplatin-kemoterapi, respons pr. behandlingsgruppe og fase
Proportion of patients receiving cisplatin chemotherapy responding by treatment group and phase
Andelen af patienter, der fik et molekulært respons på ≤0,01 % og ≤0,0032 % ved IS på forskellige tidspunkter er angivet i tabel 6 og andelen af patienter, der fik et molekylært respons på ≤0,01 % og
The proportion of patients who had a molecular response of ≤0.01% and ≤0.0032% by IS at different time points are presented in Table 6 and the proportion of patients who had a molecular response of
Andelen af patienter, der fik kemoterapi med antracyklin og cyklophosphamid, respons pr. behandlingsgruppe og fase – cyklus 1
Proportion of patients receiving anthracycline and cyclophosphamide chemotherapy responding by treatment group and phase – cycle 1
Andelen af patienter, der fik placebo og nåede dette mål, var på henholdsvis 28 % og 26 %.
The proportions of patients taking placebo who achieved this goal were 28% and 26% respectively.
Andelen af patienter, der fik Quinsair gennem studie 209’s kerne- og forlængelsesfaser (med et højeste levofloxacin-MIC-P. aeruginosa-isolat, der oversteg 1 µg/ml), var omtrent den samme ved behandlingsafslutning i cyklus 1 og 3 i kernefasen (76,6% til 83,3%) og ved behandlingsafslutning i cyklus 4 til 6 i forlængelsesfasen (77,8% til 87,5%).
The proportion of patients who received Quinsair throughout Study 209 Core and Extension Phases (with a highest levofloxacin MIC P. aeruginosa isolate exceeding 1 µg/ml) was similar at the end of treatment during Cycles 1 and 3 in the Core Phase (76.6% to 83.3%) and at the end of treatment during Cycles 4 to 6 in the Extension Phase (77.8% to 87.5%).
Andelen af patienter, der gennemførte forsøget, var signifikant højere for patienter i behandling med Aripiprazole (43 %) end med halperidol (30 %).
The overall completion rate was significantly higher for patients on aripiprazole (43%) than for haloperidol (30%).
Andelen af patienter, der oplevede bivirkninger, var den samme i gruppen < 65 år og i gruppen ≥ 65 år i begge studier.
The proportion of patients experiencing AEs was similar in those aged <65 years and those aged ≥65 years in both studies.
Andelen af patienter, der oplevede fald i både legemsvægt og HbA1c, varierede fra 70 til 79 % (andelen af patienter, der havde fald i HbA1c, varierede fra 88 til 96 %).
The proportion of patients who had both a reduction in weight and HbA1c ranged from 70 to 79 % (the proportion of patients who had a reduction of HbA1c ranged from 88 to 96 %).
Andelen af patienter, der opnåede en BCR-ABL-ratio på ≤0,0032% (4,5-log-reduktion) til enhver tid, var større i SPRYCEL- gruppen end i imatinib-gruppen (44% versus 34%).
The proportion of patients achieving BCR-ABL ratio of ≤0.0032% (4.5-log reduction) at any time was higher in the SPRYCEL group compared to the imatinib group (44% versus 34%).
Andelen af patienter, der opnåede en BCR-ABL-ratio på ≤0,01% (4-log-reduktion) til enhver tid, var større i SPRYCEL-gruppen end i imatinib-gruppen (54,1% versus 45%).
The proportion of patients achieving BCR-ABL ratio of ≤0.01% (4-log reduction) at any time was higher in the SPRYCEL group compared to the imatinib group (54.1% versus 45%).
Andelen af patienter, der opnåede et modificeret PsA Response Criteria (PsARC)-respons var højere blandt patienter behandlet med Cosentyx (38,4 %, 62,0 % og 63,0 % for henholdsvis 75 mg, 150 mg og 300 mg) sammenlignet med placebo (29,6 %) ved uge 24.
The proportion of patients achieving a modified PsA Response Criteria (PsARC) response was greater in the Cosentyx-treated patients (38.4%, 62.0% and 63.0% for 75 mg, 150 mg and 300 mg, respectively) compared to placebo (29.6%) at Week 24.
Andelen af patienter, der opnåede HbA1c < 7 % i uge 24 i studiet med tillægsbehandling med dapagliflozin til saxagliptin plus metformin, var højere i saxagliptin plus dapagliflozin plus metformin-gruppen 35,3 % (95 % CI: 28,2-42,2), sammenlignet med placebo plus dapagliflozin plus metformin-gruppen 23,1% (95 % CI: 16,9-29,3).
The proportion of patients achieving HbA1c < 7 % at week 24 for add-on therapy with dapagliflozin to saxagliptin plus metformin trial was higher in the saxagliptin plus dapagliflozin plus metformin group 35.3 % (95 % CI [28.2, 42.2]) compared to the placebo plus dapagliflozin plus metformin group 23.1 % (95 % CI [16.9, 29.3]).
Andelen af patienter, der opnåede HbA1c < 7,0 % i uge 24 i studiet med behandling med saxagliptin som tillæg til dapagliflozin plus metformin, var højere i saxagliptin plus dapagliflozin plus metformin-gruppen 38,0% (95 % CI: 30,9-45,1), sammenlignet med placebo plus saxagliptin plus metformin-gruppen 12,4% (95 % CI: 7,0-17,9).
The proportion of patients achieving HbA1c < 7.0 % at Week 24 in the add-on therapy with saxagliptin to dapagliflozin plus metformin trial was higher in the saxagliptin plus dapagliflozin plus metformin group 38.0 % (95 % CI [30.9, 45.1]) compared to the placebo plus saxagliptin plus metformin group 12.4 % (95 % CI [7.0, 17.9]).
Andelen af patienter, der rapporterede alle bivirkninger og bivirkninger af grad 3 og 4, efter genbehandling med flere MabThera serier var sammenlignelig med andelen af patienter, der rapporterede bivirkninger efter induktionsbehandling (alle bivirkninger og bivirkninger af grad 3 og 4)
The percentage of patients reporting ADRs upon re-treatment with further courses of MabThera was similar to the percentage of patients reporting ADRs upon initial exposure (any grade and grade 3/4 ADRs).
Andelen af patienter, der rapporterede bivirkninger af enhver sværhedsgrad og bivirkninger af grad 3 og 4, efter behandling med flere MabThera-serier var sammenlignelig med andelen af patienter, der rapporterede bivirkninger efter induktionsbehandling (bivirkninger af enhver sværhedsgrad og bivirkninger af grad 3 og 4)
The percentage of patients reporting ADRs upon re-treatment with further courses of MabThera was similar to the percentage of patients reporting ADRs upon initial exposure (any grade and grade 3/4 ADRs).
Andelen af patienter, der seponerede behandlingen permanent pga. bivirkninger, var 11 % i ONIVYDE + 5-FU/LV-gruppen og 12 % i monoterapigruppen.
The rates of adverse reactions leading to permanent treatment discontinuation were 11% for the ONIVYDE+5-FU/LV arm and 12% for the monotherapy arm.
Andelen af patienter, der seponerede behandlingen som følge af bivirkninger var højere i placebogruppen end i linagliptin 5 mg gruppen (4,4 % mod 3,3 %).
Discontinuation of therapy due to adverse events was higher in patients who received placebo as compared to linagliptin 5 mg (4.4% versus 3.3%).
Andelen af patienter, der som minimum responderede med den mindste klinisk relevante ændring (MCID) på 1 enhed i TDI fokal score ved uge 24, var større for Anoro (58 %) sammenlignet med placebo (41 %) og hver monoterapikomponent (53 % for umeclidinium og 51 % for vilanterol).
The proportion of patients who responded with at least the minimum clinically important difference (MCID) of 1 unit TDI focal score at Week 24 was greater for ANORO (58%) compared with placebo (41%) and each monotherapy component (53% for umeclidinium and 51% for vilanterol).
Andelen af patienter, der som minimum responderede med den mindste klinisk relevante ændring (MCID) på 1 enhed i TDI fokal score ved uge 24, var større for Laventair (58 %) sammenlignet med placebo (41 %) og hver monoterapikomponent (53 % for umeclidinium og 51 % for vilanterol).
The proportion of patients who responded with at least the minimum clinically important difference (MCID) of 1 unit TDI focal score at Week 24 was greater for LAVENTAIR (58%) compared with placebo (41%) and each monotherapy component (53% for umeclidinium and 51% for vilanterol).
Andelen af patienter, der som minimum responderede med MCID i SGRQ-score (defineret som et fald på 4 enheder i forhold til baseline) ved uge 24, var større for Anoro (49 %) sammenlignet med placebo (34 %) og hver monoterapikomponent (44 % for umeclidinium og 48 % for vilanterol).
The proportion of patients who responded with at least the MCID in SGRQ score (defined as a decrease of 4 units from baseline) at Week 24 was greater for ANORO (49%) compared with placebo (34%) and each monotherapy component (44% for umeclidinium and 48% for vilanterol).
Andelen af patienter, der som minimum responderede med MCID i SGRQ-score (defineret som et fald på 4 enheder i forhold til baseline) ved uge 24, var større for Laventair (49 %) sammenlignet med placebo (34 %) og hver monoterapikomponent (44 % for umeclidinium og 48 % for vilanterol).
The proportion of patients who responded with at least the MCID in SGRQ score (defined as a decrease of 4 units from baseline) at Week 24 was greater for LAVENTAIR (49%) compared with placebo (34%) and each monotherapy component (44% for umeclidinium and 48% for vilanterol).